Merck (NYSE:MRK) Cash And Cash Equivalents

: $5,660 Mil (As of Jun. 2023)

View and export this data going back to 1949. Start your Free Trial

Merck's quarterly cash and cash equivalents declined from Dec. 2022 ($12,694.00 Mil) to Mar. 2023 ($9,707.00 Mil) but then stayed the same from Mar. 2023 ($9,707.00 Mil) to Jun. 2023 ($5,660.00 Mil).

Merck's annual cash and cash equivalents increased from Dec. 2020 ($8,050.00 Mil) to Dec. 2021 ($8,096.00 Mil) and increased from Dec. 2021 ($8,096.00 Mil) to Dec. 2022 ($12,694.00 Mil).

Merck Cash And Cash Equivalents Historical Data

The historical data trend for Merck's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash And Cash Equivalents

7,965.00

9,676.00

8,050.00

8,096.00

12,694.00

Merck Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Cash And Cash Equivalents																9,675.00	11,145.00	12,694.00	9,707.00	5,660.00

Merck Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Merck (NYSE:MRK) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Merck Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Merck's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Merck (NYSE:MRK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (NYSE:MRK) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

MRK:Peru MRK:Mexico 6MKd:UK 0QAH:UK 6MK:Germany 6MK:Germany 6MK:Germany 6MK:Germany MRCK34:Brazil MRK:Austria MRK:Argentina

Address

126 East Lincoln Avenue, Rahway, NJ, USA, 07065

Website

https://www.merck.com

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Executives

Joseph Romanelli	officer: President, Human Health Int?l	126 EAST LINCOLN AVENUE, RAHWAY NJ 07065
Chirfi Guindo	officer: Chief Marketing Officer	C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Baker Douglas M Jr	director	370 WBASHA ST NORTH, ST PAUL MN 55102
Johannes Jacobus Oosthuizen	officer: SVP, U.S. Market	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Arpa Garay	officer: SVP Human Health Global Mktg.	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Cristal N Downing	officer: Chief Comm. & Public Afrs Ofcr	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Michael A Klobuchar	officer: EVP - Chief Strategy Officer	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Lisa Lecointe-cephas	officer: SVP Chief Ethics & Com Officer	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Caroline Litchfield	officer: EVP & CFO	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Stephen Mayo	director	2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Dean Y Li	officer: Executive VP & President, MRL	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
David Michael Williams	officer: EVP,Chief Info&Digital Officer	MERCK & CO., INC., 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Risa J Lavizzo-mourey	director	GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE ST., CHICAGO IL 60661
Christine E Seidman	director	MERCK & CO., INC., 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Kathy J Warden	director	2980 FAIRVIEW PARK DRIVE, FALLS CHURCH VA 22042